High levels of lipoprotein(a) (Lp(a)) are a genetically determined independent risk factor for cardiovascular disease that cannot be modified through lifestyle changes. Now, a study in Nature reports ...

If you've listened to the radio or opened a webpage in the past year, you may have seen or heard ads promoting lipoprotein(a), or Lp(a), testing to help people identify risks for heart disease. But, ...

Experts discuss the integration of Lp(a) testing into cardiovascular risk assessment, and refining preventive strategies and statin use in specific groups. This is a video synopsis/summary of an ...

Icosapent ethyl (Vascepa; Amarin) remains effective at reducing cardiovascular events in patients with elevated triglycerides but relatively well-controlled LDL cholesterol on a statin irrespective of ...

Please provide your email address to receive an email when new articles are posted on . Lepodisiran greatly lowered lipoprotein(a) at 6 months and 1 year compared with placebo. A cardiovascular ...

Experts discuss the current prevalence of lipoprotein(a) (Lp[a]) testing in the US, both in the general population and among those with established atherosclerotic cardiovascular disease (ASCVD), its ...

Lipoprotein(a), the low-density lipoprotein (LDL)-like particle that is currently the focus of so much enthusiastic research, is significantly more atherogenic than LDL cholesterol, according to a ...

Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...

Please provide your email address to receive an email when new articles are posted on . Lp(a) fluctuates throughout a woman’s lifetime. High levels are linked to adverse pregnancy outcomes. Data are ...